Multicenter Clinical Evaluation of Etest Meropenem-Vaborbactam (bioMérieux) for Susceptibility Testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa

Meropenem-vaborbactam (MEV) is a novel carbapenem–beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections, including pyelonephritis, in adults. In this study, we evaluated the performance of Etest M...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Microbiol
Main Authors: Jean, Sophonie, Garrett, Sheri, Anglade, Claire, Bridon, Laurence, Davies, Leanne, Garner, Omai B., Richards, Jennifer, Wallace, Meghan, Wootton, Mandy, Burnham, Carey-Ann D.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2019
Assuntos:
Bacteriology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6935911/
https://ncbi.nlm.nih.gov/pubmed/31619532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JCM.01205-19
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares